- NCIt
- C9466
Loading cancer entity…
Loading cancer entity…
Clinical trials
994 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (85)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05524168 | SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma | active not recruiting | Phase 2 | 41 | Sun Yat-sen UniversityOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT07311772 | Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid | recruiting | Phase 3 | 386 | Sun Yat-sen UniversityOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT05600842 |
| De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx |
| recruiting |
| — |
| 111 |
| University of California, IrvineOTHER |
| 1 |
| May 5, 2026 |
| clinicaltrials |
| NCT07567742 | Taurine for the Prevention and Treatment of Radiation-induced Oral Mucositis in Patients With Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 130 | Sun Yat-sen UniversityOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07013461 | International Collaborative Study on AJCC/UICC TNM-10 for Nasopharyngeal Cancer | recruiting | — | 5,000 | The University of Hong Kong-Shenzhen HospitalOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT07565389 | Evaluating Ivonescimab in PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma(AK112) | not yet recruiting | Phase 2 | 42 | National University Hospital, SingaporeOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT04944914 | Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma | recruiting | Phase 3 | 188 | Sun Yat-sen UniversityOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT05531916 | Compression Therapy as a Prophylactic Method Against CIPN: a Prospective Self-controlled Trial(CIPN) | active not recruiting | N/A | 182 | Sun Yat-sen UniversityOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT05714657 | Shortened Course Adjuvant Radiotherapy Following TORS | active not recruiting | Phase 2 | 104 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07555860 | Becotatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 28 | Sun Yat-sen UniversityOTHER | 0 | Apr 29, 2026 | clinicaltrials |
| NCT04564989 | Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC | recruiting | — | 220 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07552883 | Pseudomembrane Removal for Post-RT Nasopharyngeal Necrosis(EPoRN) | not yet recruiting | N/A | 40 | Jiangxi Provincial Cancer HospitalOTHER | 0 | Apr 27, 2026 | clinicaltrials |
| NCT05108870 | TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers | active not recruiting | Phase 1 / Phase 2 | 35 | University of ChicagoOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT05268614 | Risk Adapted De-Intensification of Radio-Chemotherapy for Oropharyngeal Squamous Cell Carcinoma | recruiting | Phase 2 | 250 | University of FloridaOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT05491512 | A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer | recruiting | Phase 2 | 121 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07548268 | Transoral and Cervical Ultrasound of Patients With Suspected Oropharyngeal Cancer | recruiting | N/A | 180 | Tobias TodsenOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06356272 | Oropharynx (OPX) Biomarker Trial | recruiting | — | 560 | Mayo ClinicOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT07540390 | GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC. | not yet recruiting | Phase 3 | 442 | Sun Yat-sen UniversityOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT06118333 | A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01) | active not recruiting | Phase 3 | 386 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT03010150 | Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer | recruiting | — | 471 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT04870762 | Customized 3D Printed Oral Stents During Head and Neck Radiotherapy | recruiting | Phase 2 | 119 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05232851 | A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer | active not recruiting | Phase 1 / Phase 2 | 20 | Mayo ClinicOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT06093061 | Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma | recruiting | Phase 2 | 53 | National Cancer Centre, SingaporeOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT03323463 | Major De-escalation to 30 Gy for Select Human Papillomavirus Associated Oropharyngeal Carcinoma | active not recruiting | Phase 2 | 316 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05307939 | A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC) | recruiting | Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07423078 | Window of Opportunity in Preserving Laryngeal Function Trial(WOLF) | recruiting | Phase 2 | 87 | Matthew SpectorOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07496190 | Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy | recruiting | Phase 2 | 59 | Sun Yat-sen UniversityOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07524413 | Becotatug Vedotin (MRG003) With PD-1 Blockade and Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma | not yet recruiting | Phase 3 | 514 | Sun Yat-sen UniversityOTHER | 0 | Apr 13, 2026 | clinicaltrials |
| NCT05483374 | The Head and Neck Registry of the European Reference Network on Rare Adult Solid Cancers(EURACAN) | recruiting | — | 13,600 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 3 | Apr 3, 2026 | clinicaltrials |
| NCT05587543 | Clinical Study on the EBV CAR-T /TCR-T Cells in the Treatment of Nasopharyngeal Carcinoma | recruiting | Early Phase 1 | 24 | Fudan UniversityOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT01898494 | Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer | active not recruiting | Phase 2 | 519 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Apr 1, 2026 | clinicaltrials |
| NCT05387915 | Biomarker-Driven Radiation Therapy Dose Reduction After Transoral Robotic Surgery for the Treatment of HPV-Positive Oropharyngeal Cancer | active not recruiting | Phase 2 | 33 | Emory UniversityOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07247201 | Integrating Allogeneic NK Cells in High-risk Advanced Stage III-IV Nasopharyngeal Cancer Patients(AlloNK1) | not yet recruiting | Phase 1 / Phase 2 | 31 | Singapore General HospitalOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT03410615 | Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC | active not recruiting | Phase 2 | 129 | Canadian Cancer Trials GroupNETWORK | 4 | Mar 24, 2026 | clinicaltrials |
| NCT06323460 | Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer | recruiting | Phase 2 | 45 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT02287311 | Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)(MABEL) | active not recruiting | Phase 1 | 38 | Baylor College of MedicineOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07320963 | Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma. | not yet recruiting | Phase 1 / Phase 2 | 52 | Sun Yat-sen UniversityOTHER | 0 | Mar 20, 2026 | clinicaltrials |
| NCT05539638 | The Role of Circulating Tumour DNA in Head and Neck Cancer | recruiting | — | 250 | University of EdinburghOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07362979 | Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma | recruiting | Phase 2 | 243 | Sun Yat-sen UniversityOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07459296 | Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC | recruiting | Phase 3 | 266 | First Affiliated Hospital of Guangxi Medical UniversityOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT06030440 | De-Intensification of Postoperative Radiotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck(DIREKHT2) | recruiting | Phase 2 / Phase 3 | 508 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT07412314 | Proton Therapy for Recurrent Nasopharyngeal Carcinoma | recruiting | N/A | 52 | Guangzhou Concord Cancer CenterOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07457099 | Impact of Postoperative Radiotherapy Versus PD-1 Inhibitor Maintenance on Survival in Resectable Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma | not yet recruiting | — | 85 | Zhujiang HospitalOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT06239727 | Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response | recruiting | Phase 3 | 593 | Sun Yat-sen UniversityOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT02597426 | Nasopharyngeal Carcinoma Post IMRT | active not recruiting | — | 108 | University Health Network, TorontoOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT06868433 | TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer | recruiting | Phase 1 | 40 | Emory UniversityOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT07327216 | Sapylin Versus Dexamethasone Inhalation for CCRT-Induced Oral Mucositis in Nasopharyngeal Carcinoma | recruiting | Phase 3 | 180 | Affiliated Hospital of Guangdong Medical UniversityOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT07044635 | Shortened Course of Radiation Therapy After Trans-oral Robotic Surgery in Patients With HPV-Mediated Oropharyngeal Squamous Cell Carcinoma.(RAD RAPTORS) | recruiting | Phase 2 | 42 | University of UtahOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07428148 | Lattice-Based Radiotherapy and Chemoimmunotherapy for Oropharyngeal Squamous Cell Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 60 | NYU Langone HealthOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT07063212 | A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC) | recruiting | Phase 2 | 40 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 19, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 7, 2026source: clinicaltrials